Creating a new RNA-based treatment to control blood clotting during heart procedures
Official title: Development of an RNA-based anticoagulant and antidote for precise on/off coagulation control during cardiovascular procedures
Funded at Helixomer, INC. · NIH-10916174 · Data updated 2026-11-12
This study is testing a new RNA-based blood thinner and its antidote to help keep your blood at the right level during heart surgeries, making the process safer and more effective for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Helixomer, INC. NIH-funded |
| Lab location | 1 site (Hillsborough, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,058,454 |
| NIH project number | 5R44HL167436-02 |
| Project ID | NIH-10916174 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients scheduled for cardiovascular surgeries who require anticoagulation therapy.
✕Less likely to help
Patients who are not undergoing surgical procedures or those with contraindications to anticoagulation therapy may not benefit from this research.
What this research studies
This research focuses on developing an innovative RNA-based anticoagulant and its antidote to provide precise control over blood coagulation during cardiovascular procedures. The approach aims to address the limitations of traditional anticoagulants like unfractionated heparin, which can cause serious side effects and variability in patient response. By utilizing RNA technology, the research seeks to create a safer and more effective method for managing blood clotting, potentially reducing the risk of complications during surgeries. Patients undergoing procedures such as open-heart surgery may benefit from this new treatment, which aims to enhance safety and efficacy.
Why it matters
Potential benefit: If successful, this research could lead to safer surgical procedures with reduced risks of blood clotting complications for patients.
How similar studies have gone: While traditional anticoagulants have been widely used, this RNA-based approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Helixomer, INC.
Hillsborough, United States Active
Researchers
- Principal investigator: Krissanaprasit, Abhichart — Helixomer, INC.
- Study coordinator: Krissanaprasit, Abhichart
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.